ABOS - Acumen Pharmaceuticals, Inc.

2.48
-0.090   -3.629%

Share volume: 250,209
Last Updated: 05-12-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$2.57
-0.09
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.13%
1 Month
-1.20%
3 Months
-1.20%
6 Months
37.02%
1 Year
136.19%
2 Year
-26.19%
Key data
Stock price
$2.48
P/E Ratio 
N/A
DAY RANGE
$2.44 - $2.62
EPS 
-$1.94
52 WEEK RANGE
$0.97 - $3.60
52 WEEK CHANGE
$153.06
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
72.213 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$288,528
AVERAGE 30 VOLUME 
$317,464
Company detail
CEO: Daniel J. O'Connell
Region: US
Website: acumenpharm.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage.

Recent news